ReviewFrontiers in endocrinology2023
Visceral fat and attribute-based medicine in chronic kidney disease.
Review in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Risk factor obesity: treatment standard.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026Review
- Attribute-based cross-classification reveals sex- and age-specific prognostic impact of anemia in ADPKD.Clinical and experimental nephrology · 2026Article
- Association of anthropometric and biochemical-anthropometric obesity indices with chronic kidney disease in diabetes: a KNHANES-based study.Clinical and experimental nephrology · 2026Article
- Lipid accumulation product and its association between new onset stroke among middle age and elderly population.BMC cardiovascular disorders · 2026Article
- Association between visceral adipose tissue measured by deep neural network architecture and chronic kidney disease.Scientific reports · 2026Article
- Association of anemia with long-term renal prognosis in autosomal dominant polycystic kidney disease using time-series analysis.Scientific reports · 2026Article
- Independent and combined associations of body mass index and visceral fat area with kidney function decline in a healthy Japanese urban population: a longitudinal study.BMC nephrology · 2026Article
- Age-adjusted visceral adiposity index as a predictor of chronic kidney disease: insights from NHANES 2007-2018.Renal failure · 2025Article
- Salt sensitivity of blood pressure: mechanisms and sex-specific differences.Nature reviews. Cardiology · 2025Review
- Attribute based cross classification analyses from the BRIGHTEN study reveal that therapeutic responsiveness to erythropoiesis stimulating agents predicts cardiorenal prognosis in renal anemia.Scientific reports · 2025Article
- Association of the dietary inflammation index with the prevalence of stroke in patients with diabetes.Scientific reports · 2025Article
- The association between the cardiac metabolic index and rapid kidney function decline and CKD in individuals with different glucose metabolism statuses: results from the China health and retirement longitudinal study.Lipids in health and disease · 2025Article
- A comparison between radiomic biological age and chronological age in estimating kidney function.Scientific reports · 2025Article
- The association between visceral fat metabolic score and stroke: mediation by declining kidney function.Diabetology & metabolic syndrome · 2025Article
- Causality of visceral adipose tissue on chronic kidney disease and renal function measure indicators, and mediation role of hypertension: Mendelian randomization study.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2025Review
- Association between cardiometabolic index and albuminuria: Evidence from NHANES 2017-2020.PloS one · 2025Article
- Association between estimated glucose disposal rate and the risk of atherosclerotic cardiovascular disease: insight from cross-sectional and retrospective cohort studies.Frontiers in nutrition · 2025Article
- Association between uric acid to high-density lipoprotein cholesterol ratio and chronic kidney disease in Chinese patients with type 2 diabetes mellitus: a cross-sectional study.Frontiers in nutrition · 2025Article
- The association of visceral adiposity index and diabetic kidney disease in elderly patients with type 2 diabetes mellitus: a cross-sectional study.Frontiers in nutrition · 2025Article
- Machine learning prediction of metabolic dysfunction-associated fatty liver disease risk in American adults using body composition: explainable analysis based on SHapley Additive exPlanations.Frontiers in nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Visceral adipose tissue plays a central role in obesity and metabolic syndrome and is an independent risk factor for both cardiovascular and metabolic disorders. Increased visceral adipose tissue promotes adipokine dysregulation and insulin resistance, leading to several health issues, including systemic inflammation, oxidative stress, and activation of the renin-angiotensin-aldosterone system. Moreover, an increase in adipose tissue directly and indirectly affects the kidneys by increasing renal sodium reabsorption, causing glomerular hyperfiltration and hypertrophy, which leads to increased proteinuria and kidney fibrosis/dysfunction. Although the interest in the adverse effects of obesity on renal diseases has grown exponentially in recent years, the relationship between obesity and renal prognosis remains controversial. This may be attributed to the long clinical course of obesity, numerous obesity-related metabolic complications, and patients' attributes. Multiple individual attributes influencing the pathophysiology of fat accumulation make it difficult to understand obesity. In such cases, it may be effective to elucidate the pathophysiology by conducting research tailored to individual attributes from the perspective of attribute-based medicine/personalized medicine. We consider the appropriate use of clinical indicators necessary, according to attributes such as chronic kidney disease stage, level of visceral adipose tissue accumulation, age, and sex. Selecting treatments and clinical indicators based on individual attributes will allow for advancements in the clinical management of patients with obesity and chronic kidney disease. In the clinical setting of obesity-related nephropathy, it is first necessary to accumulate attribute-based studies resulting from the accurate evaluation of visceral fat accumulation to establish evidence for promoting personalized medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.